AllSci News
Alpha DaRT shows early signs of boosting pembrolizumab responses in head and neck cancer
Alpha Tau Medical Ltd. (Jerusalem, Israel) (Nasdaq: DRTS, DRTSW) reported that Alpha DaRT, its intratumoral alpha-emitting radiotherapy device, produced a...
Imunon's IL-12 gene therapy shows early safety signal while reducing ovarian cancer residual disease
Imunon, Inc. (Lawrenceville, New Jersey; Nasdaq: IMNN) reported preliminary Phase II data for IMNN-001 in newly diagnosed advanced ovarian cancer, drawn...
TYK Medicines secures USD 408 million from Qilu for China lung cancer drug rights
TYK Medicines, Inc. (HKEX: 2410), a Huzhou, China-based oncology drug developer, has struck a license and collaboration agreement with Qilu Pharmaceutical...
Celldex ends barzolvolimab prurigo nodularis study after Phase II miss
Celldex Therapeutics (Hampton, New Jersey; Nasdaq: CLDX) reported topline results from a Phase II study of subcutaneous barzolvolimab in prurigo nodularis,...
Roche's USD 700m deal for Nurix's BTK degrader clears antitrust review
Nurix Therapeutics (Nasdaq: NRIX) said its global collaboration with Roche to co-develop and co-commercialize bexobrutideg (NX-5948) has closed following...
Estrigenix secures seed financing to advance Marquette- and UWM-sourced estrogen receptor-beta platform
Milwaukee-based Estrigenix Therapeutics, a biotechnology company developing selective estrogen receptor-beta (ERβ) therapeutics, has announced the first...
Novartis Q2'26: AOC FDA filing and FSHD biomarker progress as H2 catalyst slate builds
Novartis AG (NYSE: NVS) held its Novartis Q2 2026 earnings call on July 21, 2026, during which executives detailed the company's first FDA submission for an...
Curatix secures NIAID support for drug-resistant fungal infection adjuvants
The Small Business Innovation Research (SBIR) mechanism at the National Institute of Allergy and Infectious Diseases (NIAID) has awarded a USD 1.0 million...
Nuvation expands safusidenib program into post-vorasidenib IDH1-mutant glioma
Nuvation Bio Inc. (NYSE: NUVB) reported updated long-term data on Monday from the safusidenib clinical trial in IDH1-mutant glioma, alongside plans to...
Kolon's TG-C Phase III failure slows cell therapy push into knee osteoarthritis
Kolon TissueGene's first pivotal test of a cell and gene therapy for knee osteoarthritis has come back negative, complicating a development program that...
Lupin spins out PRMT5 and SOS1 oncology programs into equity-backed Kaveri
Lupin Limited (BSE: 500257, NSE: LUPIN) has moved two clinical-stage oncology assets off its own balance sheet and into a newly formed company, in a...
Engitix taps Lonza's ADC platform to target cancer through extracellular matrix discovery
Basel, Switzerland-based Lonza (SIX: LONN) has granted London-based Engitix Therapeutics a single-target license to its antibody-drug conjugate technology...
Merakris picks up NIH grant to support MTX-001 into diabetic foot ulcer trials
Merakris Therapeutics, a Research Triangle Park, North Carolina-based clinical-stage biotechnology company, has received a Direct-to-Phase II Small Business...
MaxCyte licenses cell-engineering platform to Genentech across multiple programs
MaxCyte, Inc. (Nasdaq: MXCT), a Rockville, Maryland-based cell-engineering company, has entered a multi-platform technology license with Genentech, a member...
AbelZeta’s CD19/BCMA-targeted CAR-T advances into European fast-track for refractory lupus
AbelZeta Pharma, a clinical-stage biopharmaceutical company with operations in Rockville, Maryland and Shanghai, China, announced receipt of PRIority MEdicines (PRIME) designation from…
The AllSci Brief
Free, systematic R&D and deal news. Daily.